CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to update the labels of Jardiance (empagliflozin), Synjardy (empagliflozin and metformin) and Glyxambi (empagliflozin and linagliptin) to include additional important data from the landmark EMPA-REG OUTCOME trial on heart failure and kidney endpoints.